REDWOOD CITY, Calif., Sept. 6, 2011 /PRNewswire/ -- Pearl Therapeutics was named by FierceBiotech today as one of 2011's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech's ninth annual Fierce 15 selection.
"Pearl's veteran team has done a super job of raising the funds and doing clinical research to advance PT003 – an inhaled LAMA/LABA combination therapy – toward the market," says Ryan McBride, the executive editor for FierceBiotech. "I believe the company is positioned well to gain marketing partners for the treatment."
Chuck Bramlage, Pearl's chief executive officer continued, "Earlier in 2011, following our $69 million Series C financing, we were named by FierceBiotech to the list of 15 top venture capital deals in biotechnology. Today's Fierce 15 award speaks not only to our fundraising ability, but to the commitment, expertise and passion with which the Pearl team pursues product development. I look forward to continuing to work with this exceptional team in our development of our lead COPD candidate, PT003, and living up to the 'fierce' moniker in fighting major respiratory ailments."
An internationally recognized daily newsletter reaching more than 90,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick, authoritative briefing on the day's top stories. Every year FierceBiotech evaluates hundreds of private companies for its annual list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. A complete list of "Fierce 15" companies – the online newsletter's ninth annual selection – is available online at www.fiercebiotech.com.
About Pearl Therapeutics
Pearl Therapeutics is a privately held company developing combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease and asthma. Pearl is rapidly advancing a pipeline of products including PT003, an inhaled, fixed-dose combination bronchodilator product comprised of a long-acting muscarinic antagonist (LAMA) and a long-acting beta-2 agonist (LABA) delivered via a metered dose inhaler (HFA MDI); and PT010, a triple-combination product that combines the LAMA and LABA components of PT003 with an inhaled corticosteroid (ICS) for twice-daily administration from an HFA MDI for the treatment of severe COPD. Both PT003 and PT010 are developed with Pearl's proprietary porous particle cosuspension technology, which allows the formulation of multiple products in the MDI format, with highly stable, robust and aerodynamically efficient drug delivery. Founded in 2006, Pearl Therapeutics is privately held and backed by 5AM Ventures, Clarus Ventures, New Leaf Ventures and Vatera Healthcare. For more information, please visit www.pearltherapeutics.com.
FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 90,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Sign up is free at www.fiercebiotech.com.
SOURCE Pearl Therapeutics